Search
  • Friday Capital

IMMUNO-ONCOLOGY THERAPEUTICS - Investment Environment

Although these days the race to develop a COVID-19 vaccine is taking centre stage in the current biosciences environment, oncology still plays a key role as being the next largest area for investment activity. Before COVID-19 struck, oncology represented nearly half of the buy-side transactions for the large pharma dealmakers, and topped US venture capital funding by disease area. Most oncology therapy deals are characterised by M&A (70%) whereas licensing makes up much less of the total (27%).


Our Q4 2020 report provides an in-depth analysis of this dynamic investment environment along with the latest developments in the field of immuno-oncology therapeutics.


Table of contents:


  • Deal Landscape

  • M&A Deals

  • Licensing Deals

  • Venture Capital

  • Key Immuno-Oncology Therapies

  • CAR-T

  • CRISPR

  • Neoantigen Vaccines

  • Checkpoint Inhibitors

  • Combination Therapies

  • Biomarkers

  • Companion Diagnostics

  • Next Generation Sequencing

  • Clinical Trials

You can download our report from here:


Friday_Capital_Report_Immuno_Oncology_Q4
.
Download • 3.39MB

For further details and enquiries please contact Anthony Vago at anthony.vago@friday.capital.


Friday Capital is proud to be an accredited indigenous organisation by Supply Nation.

Friday Capital | Level 5, 151 Castlereagh Street, Sydney  NSW 2000 | ABN: 93 633 250 067 | Australian Financial Services License No. 521472

The information contained on this website has been provided as general advice to wholesale clients only and is intended for informational purposes. The contents of the website have been prepared without taking into account your objectives, financial situation or needs. Before you make any decision regarding any information, strategies or products mentioned on this website, you should consult your own financial advisor to consider what is appropriate having regard to your own objectives, financial situation and needs.